# Panacea Biotec share price today (Panacea Biotec Ltd, NSE: PANACEABIO)

> Panacea Biotec share price today: ₹334.75 at the NSE close on 3 November 2026, down 23.6% in a year. Panacea Biotec (NSE: PANACEABIO) is worth ₹2,052 crore and has closed between ₹311.45 and ₹607.75 over the past 52 weeks. > Panacea Biotec Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. PANACEABIO · Pharma - Others · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/panacea-biotec-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: ₹334.75 (−23.6% in a year)
- Revenue (Jun 2026): ₹200 Cr (+19.7% on a year ago)
- Profit (Jun 2026): ₹2.2 Cr (−44.4% on a year ago)
- Operating margin: 2.8% (+3.5 points on a year ago)
- ROCE: −2%, FY26
- ROIC: −3.9%, against a 12.0% cost of capital: −15.9 points

The main question: profits are rising, but only 0% of the last 2 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch. ## What is the Panacea Biotec share price today? Panacea Biotec Ltd's share price was ₹334.75 at the close on 3 November 2026. It has been falling for 6 weeks. That is 16.3% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹311 and ₹608, and at that close it sat 8% of the way up from that low. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 16 weeks running. Over the last 11 years the share price moved +277% while the NIFTY 500 moved +251%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 17 July 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Panacea Biotec this quarter? Three changes stood out: indian funds and insurers (DIIs) raised their stake for 7 quarters in a row, foreign funds (FIIs) raised their stake for 5 quarters in a row and highest quarterly revenue in 15 quarters. 1. Indian funds and insurers (DIIs) raised their stake for 7 quarters in a row From 1.2% to 2.5% of the company by the September 2026 quarter. 2. Foreign funds (FIIs) raised their stake for 5 quarters in a row From 0.8% to 2.8% of the company by the September 2026 quarter. 3. Highest quarterly revenue in 15 quarters Revenue of ₹200 crore in the June 2026 quarter is the highest of the last 15 quarters. ## What are Panacea Biotec's latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Panacea Biotec reported revenue of ₹200 crore, up 19.7% from ₹167 crore a year earlier, and a profit of ₹2.20 crore, down 44.4% from ₹3.96 crore. ### Panacea Biotec results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹200 crore | ₹167 crore | +19.7% |
| Profit | ₹2.20 crore | ₹3.96 crore | −44.4% |
| Earnings per share | ₹0.38 | ₹0.66 | −42.4% |
| Operating margin | 2.8% | −0.7% | +3.6 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Panacea Biotec share price history? Panacea Biotec closed at ₹334.75 on 3 November 2026, down 23.6% from ₹437.90 a year earlier (31 October 2025) and up 56.7% over five years. Its highest weekly close since March 2016 was ₹607.75 on 9 June 2026. ### Panacea Biotec share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹311.45 | +7.5% |
| 1 month ago · 1 Oct 2026 | ₹359.05 | −6.8% |
| 6 months ago · 30 Apr 2026 | ₹361.05 | −7.3% |
| 1 year ago · 31 Oct 2025 | ₹437.90 | −23.6% |
| 3 years ago · 3 Nov 2023 | ₹154.50 | +116.7% |
| 5 years ago · 4 Nov 2021 | ₹213.60 | +56.7% |
| 10 years ago · 4 Nov 2016 | ₹107.59 | +211.1% |
| Earliest weekly close in our records · 11 Mar 2016 | ₹88.78 | +277.1% |
| Highest weekly close since March 2016, also the 52-week high · 9 Jun 2026 | ₹607.75 | −44.9% |
| Lowest weekly close since March 2016 · 27 May 2016 | ₹79.65 | +320.3% |
| 52-week low (weekly close) · 23 Oct 2026 | ₹311.45 | +7.5% |

Weekly closing prices. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (563 weekly closes from 11 March 2016 to 3 November 2026.)

## What is the latest news on Panacea Biotec? 3 Nov 2026: Panacea Biotec closed at ₹334.75, up 7.5% on the week and down 6.8% on the month. Results for April to June 2026: Revenue up 19.7% and profit down 44.4% on a year earlier. ## What dividend does Panacea Biotec pay? Panacea Biotec has paid no dividend on the NSE since 1 April 2021, the start of the period we checked. No. Panacea Biotec Ltd paid out 0% of its profit as dividends in each of its last 13 reported years, so there is no payout history to show. That comes from the filed annual statements, not an estimate. (From the NSE corporate-actions record, read 4 November 2026.)

## Which stock lists is Panacea Biotec on? Panacea Biotec is on one of our India lists: Pharma stocks. [Pharma stocks Market value (₹ crore): 2007.828411811652](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is Panacea Biotec profitable? Panacea Biotec Ltd earned ₹2.2 Cr of net profit in the Jun 2026 quarter, −44.4% on the same quarter a year earlier. The full FY26 year was a loss of ₹7.0 Cr. That is 1.1% of the quarter's revenue. The same quarter a year earlier earned ₹4.0 Cr. 7 of the last 12 reported quarters were loss-making. Why profit moved: revenue changed +19.7% on a year earlier and the margin moved +3.5 percentage points. Most of the change came from keeping more of each sale. On average over the last four quarters, profit changed −151.4% and revenue +10.6%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Panacea Biotec make, and is it growing? Panacea Biotec Ltd reported ₹200 Cr of revenue in the Jun 2026 quarter, +19.7% on the same quarter a year earlier. That is the 3rd quarter in a row with growth on the year before. Over 10 years it has grown −0.2% a year on average. The last full year, FY26, came in at ₹640 Cr. The last four reported quarters add to ₹673 Cr. FY26 revenue was ₹640 Cr, +14.5% on the year before. Recent pace: the last four quarters grew +10.6% on average, against −0.2% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +10.3%, against +11.0% a year over the last 8 quarters (stabilising). ## How much of every ₹100 of sales does Panacea Biotec keep? Panacea Biotec Ltd's operating margin was 2.8% in the Jun 2026 quarter, 3.5 percentage points higher than the same quarter a year ago. Across 13 years it has been between −29.0% and 17.0%. The latest quarter is within that range. Why the margin moved: operating margin changed +3.5 percentage points on the year while gross margin changed −4.6 points. So the gain came mostly from the gross margin, which means input costs and prices charged. ## Is Panacea Biotec's profit turning into cash? Over the last 2 years, 0% of Panacea Biotec Ltd's reported profit came in as cash from its operations, a gap worth watching. In FY26 it brought in ₹17.0 Cr of operating cash against −₹7.0 Cr of profit. After ₹58.0 Cr of spending on assets, free cash was −₹41.0 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 0% of profit came in as cash: the cash cycle got 126 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. When less than 70% of profit comes in as cash, it is the thing to watch on this page. What to look at next: less of the profit turns into cash than it should, and the cash cycle is 126 days longer. The next section looks at where the cash is stuck. ## Where does Panacea Biotec's cash go? Panacea Biotec Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 46 days in FY26, up from −80 days in FY21. It spent ₹183 Cr on assets over the last 3 years. Customers take 42 days to pay, and stock sits for 251 days on average. At FY26 sales of ₹640 Cr, each day of that cycle ties up about ₹1.8 Cr, so roughly ₹81.0 Cr is tied up in the business at any time. FY26: customers took 42 days to pay and stock sat for 251 days, about 8.3 months of sales sitting as stock, for a full cycle of 46 days, longer than FY21's −80. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 251 days. Customers pay about 42 days after that. Suppliers are paid at 247 days. Together that makes the 46-day cycle. Spending on assets: ₹183 Cr over the last 3 years, against ₹105 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹144 Cr (FY26): assets paid for that are not earning yet. In short: cash is getting stuck in the daily cycle, so watch the cycle more than the profit. ## What is Panacea Biotec's P/E ratio, and how does it compare with its own history? Panacea Biotec Ltd has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values Panacea Biotec Ltd at 3.2× its FY26 revenue of ₹640 Cr. The P/E comes back here once profit turns positive. ## Is the Panacea Biotec business getting better or worse? Panacea Biotec Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Panacea Biotec earn on its capital? Panacea Biotec Ltd earned a ROCE of −2% in FY26. That is up from a low of −16% in FY19. Its return on capital used (ROIC) is 15.9 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a −1.1% net margin and 0.51× asset turnover (sales divided by assets). Why the return is what it is (FY26): a −1.1% net margin × 0.51× asset turnover × 1.51× leverage (assets divided by equity) ≈ −0.8% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: −3.9% − 12.0% = −15.9 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. ## Does Panacea Biotec have too much debt? Panacea Biotec Ltd has total debt of ₹24.0 Cr against shareholder equity of ₹829 Cr as of Jun 2026, so its debt is 0.03× its equity, which is very little. Year by year, that ratio went from 0.04 in FY22 to 0.03 in FY26. So the returns on this page come from the business, not from borrowed money. ## What is the Panacea Biotec shareholding pattern? Foreign institutions raised their stake in Panacea Biotec Ltd by 2.4 percentage points over 8 quarters, the biggest change among its owners. Foreign institutions now own 2.8% of the company. Domestic institutions moved +1.3 points over the same period, to 2.5%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Foreign institutions: +2.4 points over 8 quarters, to 2.8%; Domestic institutions: +1.3 points over 8 quarters, to 2.5%; Promoters: −0.4 points over 8 quarters, to 72.5%. Why the owners changed: foreign institutions drove it (+2.4 points), together with domestic institutions (+1.3 points). They raised their stake step by step. ## How far is Panacea Biotec from balance-sheet trouble? For Panacea Biotec Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Panacea Biotec rank in its industry? 20.4 out of 100, rank 7 of 10 in Pharma - Others, with 76% of the evidence available. Panacea Biotec Ltd scores 20.4 out of 100 against the 10 companies it is compared with in Pharma - Others, ranking 7. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 8.2 + 1.2 + 10 + 1 = 20.4. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Panacea Biotec compared with? Panacea Biotec ranks 7 of 10 Pharma - Others companies on the 4-Factor Sector Score, with 20.4 out of 100. 1. [Syncom Formulations (India) Ltd](https://www.sectoralpha.in/stocks/syncom-formulations-indialtd) SYNCOMF · breaking out · Most evidence points up · 89% evidence 70.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.4/35 · Revenue 0.4% · Profit 48.3% · Operating margin change 7 points · 88% evidence Capital efficiency 17.2/25 · ROCE 24.7% · Operating margin 21% · 100% evidence Valuation 15.1/20 · P/E 21.2× · PEG 0.79 · 65% evidence Relative strength 17.8/20 · Lead over its industry -0.2% · Lead over NIFTY 500 32.3% · 1 year 16.7% · 100% evidence · 12 of 12 weeks ahead Exact sum: 20.4 + 17.2 + 15.1 + 17.8 = 70.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. [Shukra Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/shukra-pharmaceuticals-ltd) SHUKRAPHAR · breaking out · Too little evidence to rank firmly · 56% evidence 69.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.5/35 · Revenue 100% · Profit 100% · Operating margin change 66 points · 83% evidence Capital efficiency 19.4/25 · ROCE 37% · Operating margin 90% · 76% evidence Valuation 9.3/20 · P/E 91.9× · PEG n/a · 15% evidence Relative strength 12.5/20 · Lead over its industry n/a · Lead over NIFTY 500 83.7% · 1 year 82.8% · 25% evidence · 6 of 6 weeks ahead Exact sum: 28.5 + 19.4 + 9.3 + 12.5 = 69.7 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 3. [Sun Pharma Advanced Research Company Ltd](https://www.sectoralpha.in/stocks/sun-pharma-advanced-research-company-ltd) SPARC · quiet · Evidence leans up · 78% evidence 61.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.8/35 · Revenue 100% · Profit 100% · Operating margin change 455 points · 65% evidence Capital efficiency 16.0/25 · ROCE 164% · Operating margin -85% · 100% evidence Valuation 15.0/20 · P/E 3.6× · PEG n/a · 50% evidence Relative strength 4.3/20 · Lead over its industry -17.4% · Lead over NIFTY 500 9.3% · 1 year 30.9% · 100% evidence · 1 of 12 weeks ahead Exact sum: 25.8 + 16 + 15 + 4.3 = 61.1 · What this means: Earnings are strong; relative strength in its sector is -17.4% and the one-year return is 30.9%. 4. [Remus Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/remus-pharmaceuticals-ltd) REMUS · breaking out · Too little evidence to rank firmly · 54% evidence 54.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.5/35 · Revenue 57.3% · Profit 80% · Operating margin change -4 points · 27% evidence Capital efficiency 13.3/25 · ROCE 11.5% · Operating margin 32% · 57% evidence Valuation 11.2/20 · P/E 41.2× · PEG n/a · 50% evidence Relative strength 12.8/20 · Lead over its industry -12.6% · Lead over NIFTY 500 16.6% · 1 year 17.1% · 100% evidence · 11 of 12 weeks ahead Exact sum: 17.5 + 13.3 + 11.2 + 12.8 = 54.8 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 5. [TTK Healthcare Ltd](https://www.sectoralpha.in/stocks/ttk-healthcare-ltd) TTKHLTCARE · quiet · Evidence leans up · 85% evidence 50.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.8/35 · Revenue 11.3% · Profit 100% · Operating margin change -1 points · 100% evidence Capital efficiency 6.8/25 · ROCE 8% · Operating margin 1.6% · 100% evidence Valuation 15.7/20 · P/E 17.6× · PEG 1.38 · 100% evidence Relative strength 8.4/20 · Lead over its industry n/a · Lead over NIFTY 500 -3% · 1 year -23.1% · 25% evidence · 10 of 12 weeks ahead Exact sum: 19.8 + 6.8 + 15.7 + 8.4 = 50.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Unichem Laboratories Ltd](https://www.sectoralpha.in/stocks/unichem-laboratories-ltd) UNICHEMLAB · losing its lead · Evidence leans down · 64% evidence 38.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.4/35 · Revenue 7.2% · Profit 100% · Operating margin change 6.7 points · 62% evidence Capital efficiency 6.6/25 · ROCE 4.1% · Operating margin 11% · 76% evidence Valuation 10.0/20 · P/E 27.9× · PEG n/a · 15% evidence Relative strength 8.3/20 · Lead over its industry -13.3% · Lead over NIFTY 500 15.4% · 1 year 2.7% · 100% evidence · 8 of 12 weeks ahead Exact sum: 13.4 + 6.6 + 10 + 8.3 = 38.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. Panacea Biotec Ltd this page PANACEABIO · basing · Most evidence points down · 76% evidence 20.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 8.2/35 · Revenue 10.3% · Profit -80% · Operating margin change 3.5 points · 88% evidence Capital efficiency 1.2/25 · ROCE -2.4% · Operating margin 2.8% · 100% evidence Valuation 10.0/20 · P/E n/a · PEG n/a · 0% evidence Relative strength 1.0/20 · Lead over its industry -38.3% · Lead over NIFTY 500 -16.4% · 1 year -28.5% · 100% evidence · 0 of 12 weeks ahead Exact sum: 8.2 + 1.2 + 10 + 1 = 20.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [JOJO Ltd](https://www.sectoralpha.in/stocks/jojo-ltd) leader · Too little evidence to rank firmly · 48% evidence 61.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.1/43.75 · Revenue 100% · Profit 100% · Operating margin change 53.1 points · 62% evidence Capital efficiency 19.4/31.25 · ROCE 16.8% · Operating margin 44.7% · 95% evidence Valuation 11.1/25 · P/E 219× · PEG n/a · 15% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 31.1 + 19.4 + 11.1 = 61.6 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 9. [Jenburkt Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/jenburkt-pharmaceuticals-ltd) Too little evidence to rank firmly · 47% evidence 56.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.6/43.75 · Revenue 11.8% · Profit 6.1% · Operating margin change 6 points · 53% evidence Capital efficiency 21.8/31.25 · ROCE 27.2% · Operating margin 32% · 71% evidence Valuation 14.3/25 · P/E 13.2× · PEG n/a · 50% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 20.6 + 21.8 + 14.3 = 56.7 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 10. [Madhuveer Com 18 Network Ltd](https://www.sectoralpha.in/stocks/madhuveer-com-18-network-ltd) MADHUVEER · Too little evidence to rank firmly · 33% evidence 42.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.5/43.75 · Revenue 68.7% · Profit 12.8% · Operating margin change 18.4 points · 45% evidence Capital efficiency 11.7/31.25 · ROCE -1.1% · Operating margin 69.7% · 57% evidence Valuation 10.6/25 · P/E 660× · PEG n/a · 15% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 20.5 + 11.7 + 10.6 = 42.8 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - Others](https://www.sectoralpha.in/sectors/pharma-others), all 10 compared on one page. ## Which companies are close to Panacea Biotec in size? Panacea Biotec is the 4th largest of 10 Pharma - Others companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Sun Pharma Advanced Research Company, Unichem Laboratories and Shukra Pharmaceuticals. Just below it: Syncom Formulations (India), JOJO and TTK Healthcare. ### Pharma - Others companies close in size

1. [Sun Pharma Advanced Research Company Ltd](https://www.sectoralpha.in/stocks/sun-pharma-advanced-research-company-ltd) ₹5,727 crore
2. [Unichem Laboratories Ltd](https://www.sectoralpha.in/stocks/unichem-laboratories-ltd) ₹3,406 crore
3. [Shukra Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/shukra-pharmaceuticals-ltd) ₹3,313 crore
4. Panacea Biotec Ltd ₹1,919 crore
5. [Syncom Formulations (India) Ltd](https://www.sectoralpha.in/stocks/syncom-formulations-indialtd) ₹1,809 crore
6. [JOJO Ltd](https://www.sectoralpha.in/stocks/jojo-ltd) ₹1,539 crore
7. [TTK Healthcare Ltd](https://www.sectoralpha.in/stocks/ttk-healthcare-ltd) ₹1,279 crore

[All 10 Pharma - Others companies, largest first](https://www.sectoralpha.in/sectors/pharma-others#all-companies)

### Companies close in size in other industries

1. [Indoco Remedies Ltd](https://www.sectoralpha.in/stocks/indoco-remedies-ltd) ₹1,923 crore · Pharma - Formulators
2. [Gretex Corporate Services Ltd](https://www.sectoralpha.in/stocks/gretex-corporate-services-ltd) ₹1,919 crore · Finance & Investments - Others
3. Panacea Biotec Ltd ₹1,919 crore
4. [Oriental Aromatics Ltd](https://www.sectoralpha.in/stocks/oriental-aromatics-ltd) ₹1,916 crore · Chemicals - Organic
5. [Aayush Art and Bullion Ltd](https://www.sectoralpha.in/stocks/aayush-art-and-bullion-ltd) ₹1,915 crore · Trading

## What else do people ask about Panacea Biotec? ### What is Panacea Biotec's share price today? Panacea Biotec Ltd's share price is ₹334.75, −23.6% over the past year. The whole company is worth ₹2,052 Cr on the market. In the last 52 weeks it traded between ₹311 to ₹608; today it is 8% of the way up from the low, 16.3% below its 200-day average (as of 3 November 2026). ### What were Panacea Biotec's latest quarterly results? Panacea Biotec Ltd reported revenue of ₹200 Cr and net profit of ₹2.2 Cr for the Jun 2026 quarter. Revenue rose 19.7% and profit fell 44.4% compared with a year earlier. Earnings per share were ₹0.38. The operating margin was 2.8%, 3.5 percentage points higher than a year earlier (as of 3 November 2026). ### What is Panacea Biotec's market cap? Panacea Biotec Ltd's market capitalisation is ₹2,052 Cr at a share price of ₹334.75. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Panacea Biotec performing? Panacea Biotec Ltd's share price has been falling for 6 weeks. In its latest quarter, revenue rose 19.7% and profit fell 44.4% compared with a year earlier. Over the past 13 weeks it has done worse than the NIFTY 500, for 16 weeks running (as of 3 November 2026). ### Will Panacea Biotec's share price go up? This page does not forecast Panacea Biotec Ltd's share price. What it shows instead: the share price is ₹334.75, and it has been falling for 6 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 3 November 2026). ### Who owns Panacea Biotec? Promoters own 72.5% of Panacea Biotec Ltd, foreign institutions 2.8%, domestic institutions 2.5% and the public 22.3% (latest quarter). The biggest change over the last two years: Foreign institutions raised their stake by 2.4 percentage points over 8 quarters (as of 3 November 2026). ### Does Panacea Biotec have too much debt? No, Panacea Biotec Ltd has little debt: its debt is 0.03× its equity, and its operating profit is −1 times its interest bill. FY26 borrowings were ₹24.0 Cr against equity of ₹835 Cr. So the returns on this page come from the business, not borrowed money (as of 3 November 2026). ### Where is Panacea Biotec in its business cycle? Panacea Biotec Ltd's FY26 operating margin was −0.7%, against a 13-year range of −29.0% to 17.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 2.8%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Panacea Biotec story? The main question: profits are rising, but only 0% of the last 2 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Panacea Biotec a stock worth studying right now? What the numbers show: Panacea Biotec Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: whether the cash starts to follow the profit. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ## Lists

- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.